Apyx Medical (APYX) Expected to Announce Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $13.1750 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million for the quarter, compared to analyst estimates of $10.53 million. On average, analysts expect Apyx Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Apyx Medical Trading Down 0.5%

Shares of NASDAQ APYX opened at $3.84 on Thursday. The firm has a 50 day moving average price of $4.24 and a two-hundred day moving average price of $3.93. The stock has a market cap of $160.93 million, a P/E ratio of -17.45 and a beta of 1.37. Apyx Medical has a 52-week low of $1.59 and a 52-week high of $5.08. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Wall Street Zen lowered Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Finally, HC Wainwright began coverage on Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Apyx Medical currently has an average rating of “Moderate Buy” and a consensus target price of $6.60.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in APYX. Citadel Advisors LLC acquired a new position in shares of Apyx Medical in the 3rd quarter worth approximately $28,000. Hudson Bay Capital Management LP bought a new stake in shares of Apyx Medical in the 4th quarter valued at $73,000. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical during the second quarter worth $50,000. Franklin Resources Inc. acquired a new stake in shares of Apyx Medical during the third quarter worth $59,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Apyx Medical in the fourth quarter valued at $111,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.